Clinical Report: CGM Linked to More Time in Range

Overview

Real-time continuous glucose monitoring (CGM) improved secondary glycemic measures among insulin-treated type 2 diabetes patients on hemodialysis, including time in range and mean glucose levels.

Background

Continuous glucose monitoring is increasingly recognized for its potential to enhance glycemic control in patients with diabetes. This study specifically addresses the impact of CGM in a complex population of insulin-treated type 2 diabetes patients undergoing maintenance hemodialysis, a group at high risk for glycemic variability and hypoglycemia.

Data Highlights

Key Findings

• Real-time CGM improved mean time in the target range (63% vs 55% with capillary testing).
• Time above 180 mg/dL was lower with CGM (35%) compared to capillary testing (44%).
• Mean glucose levels were significantly lower during CGM (174 mg/dL) than during capillary testing (188 mg/dL).
• Time below 70 mg/dL did not differ significantly between the two monitoring methods.
• Approximately 79% of patients experienced glucose below 70 mg/dL during CGM, compared to 72% during capillary testing.
• Hyperglycemic episodes remained common, with all patients experiencing glucose above 180 mg/dL in both periods.

Clinical Implications

The findings indicate that real-time CGM may enhance glycemic control metrics in insulin-treated patients on hemodialysis.

Conclusion

Real-time continuous glucose monitoring demonstrated improvements in glycemic control metrics.

Related Resources & Content

1. University of Miami, Diabetes Care, 2026 -- Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial
2. American Diabetes Association, Diabetes Care, 2026 -- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes
3. The Journal of Clinical Endocrinology & Metabolism — Establishing Physiological Ranges for Continuous Glucose Monitor Time in Range Among a Large Community Cohort of Non-Diabetic Individuals
4. conexiant — Expanding CGM Access for Medicare Patients
5. conexiant — CGM in Early Gestational Diabetes Improved Outcomes
6. aace endocrine ai — Remote CGM monitoring may improve glycemic outcomes
7. Establishing Physiological Ranges for Continuous Glucose Monitor Time in Range Among a Large Community Cohort of Non-Diabetic Individuals
8. Expanding CGM Access for Medicare Patients
9. CGM in Early Gestational Diabetes Improved Outcomes
10. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
11. Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial - University of Miami
12. Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study) - PubMed